ATE165973T1 - Sumatriptan enthaltende arzneimittel - Google Patents

Sumatriptan enthaltende arzneimittel

Info

Publication number
ATE165973T1
ATE165973T1 AT92103592T AT92103592T ATE165973T1 AT E165973 T1 ATE165973 T1 AT E165973T1 AT 92103592 T AT92103592 T AT 92103592T AT 92103592 T AT92103592 T AT 92103592T AT E165973 T1 ATE165973 T1 AT E165973T1
Authority
AT
Austria
Prior art keywords
film
drugs containing
solid dosage
coated solid
containing sumatriptan
Prior art date
Application number
AT92103592T
Other languages
English (en)
Inventor
John Malcolm Padfield
Ian Keith Winterborn
Anthony John Phillips
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE165973T1 publication Critical patent/ATE165973T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Waveguide Aerials (AREA)
  • Non-Reversible Transmitting Devices (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
AT92103592T 1991-03-08 1992-03-02 Sumatriptan enthaltende arzneimittel ATE165973T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919104890A GB9104890D0 (en) 1991-03-08 1991-03-08 Compositions

Publications (1)

Publication Number Publication Date
ATE165973T1 true ATE165973T1 (de) 1998-05-15

Family

ID=42342461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92103592T ATE165973T1 (de) 1991-03-08 1992-03-02 Sumatriptan enthaltende arzneimittel

Country Status (29)

Country Link
US (4) US5863559A (de)
EP (1) EP0503440B1 (de)
JP (1) JP2986546B2 (de)
KR (1) KR100202042B1 (de)
AT (1) ATE165973T1 (de)
AU (1) AU663303B2 (de)
BE (1) BE1005086A5 (de)
CA (1) CA2105180C (de)
CH (1) CH684242A5 (de)
CY (1) CY2011A (de)
CZ (1) CZ282352B6 (de)
DE (1) DE69225421T2 (de)
DK (1) DK0503440T3 (de)
ES (1) ES2117015T3 (de)
FR (1) FR2673538B1 (de)
GB (2) GB9104890D0 (de)
GE (1) GEP20012549B (de)
HK (1) HK19395A (de)
IE (1) IE920726A1 (de)
IL (1) IL101162A (de)
IT (1) IT1271495B (de)
MX (1) MX9200992A (de)
NL (1) NL9200423A (de)
NZ (1) NZ241873A (de)
OA (1) OA09812A (de)
RU (1) RU2098093C1 (de)
SG (1) SG169294G (de)
WO (1) WO1992015295A1 (de)
ZA (1) ZA921690B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DE4314976C1 (de) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
AU2003249478A1 (en) * 2002-07-19 2004-02-09 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
EP1575566B1 (de) * 2002-12-26 2012-02-22 Pozen, Inc. Mehrschichtige dosierformen enthaltend naproxen und triptane
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
EP1765300A2 (de) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulierungen von sumatriptan zur absorption durch biologische membranen, und herstellungs- und anwendungsverfahren
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
EP3263117A1 (de) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
EP2813144A1 (de) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgetische Zusammensetzungen enthaltend ein Antihistamin
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
EP3090743A1 (de) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
EP2296652B1 (de) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topische regionale neuroaffektive therapie
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
KR101646079B1 (ko) 2009-09-25 2016-08-12 닥터 레디스 레보러터리즈 리미티드 트립탄 화합물을 포함하는 제제
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
EP3423041A4 (de) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79215B (de) * 1982-06-07 1984-10-22 Glaxo Group Ltd
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Also Published As

Publication number Publication date
DK0503440T3 (da) 1999-01-18
ITRM920155A0 (it) 1992-03-06
CZ184993A3 (en) 1994-06-15
OA09812A (en) 1994-04-15
IE920726A1 (en) 1992-09-09
CH684242A5 (fr) 1994-08-15
JP2986546B2 (ja) 1999-12-06
EP0503440B1 (de) 1998-05-13
AU663303B2 (en) 1995-10-05
SG169294G (en) 1995-04-28
US20020197318A1 (en) 2002-12-26
GB2254784A (en) 1992-10-21
CZ282352B6 (cs) 1997-07-16
GEP20012549B (en) 2001-10-25
DE69225421D1 (de) 1998-06-18
IL101162A0 (en) 1992-11-15
US6368627B1 (en) 2002-04-09
JPH06505020A (ja) 1994-06-09
IL101162A (en) 1997-11-20
GB9104890D0 (en) 1991-04-24
NZ241873A (en) 1994-06-27
CA2105180C (en) 1999-08-17
US6020001A (en) 2000-02-01
GB2254784B (en) 1994-11-16
HK19395A (en) 1995-02-17
ITRM920155A1 (it) 1993-09-06
EP0503440A1 (de) 1992-09-16
NL9200423A (nl) 1992-10-01
CY2011A (en) 1998-02-20
CA2105180A1 (en) 1992-09-09
AU1326492A (en) 1992-10-06
KR100202042B1 (ko) 1999-06-15
GB9204761D0 (en) 1992-04-15
MX9200992A (es) 1992-09-01
FR2673538A1 (fr) 1992-09-11
RU2098093C1 (ru) 1997-12-10
ZA921690B (en) 1993-08-02
FR2673538B1 (fr) 1995-05-12
WO1992015295A1 (en) 1992-09-17
IT1271495B (it) 1997-05-30
BE1005086A5 (fr) 1993-04-13
DE69225421T2 (de) 1998-10-15
US5863559A (en) 1999-01-26
ES2117015T3 (es) 1998-08-01

Similar Documents

Publication Publication Date Title
ATE165973T1 (de) Sumatriptan enthaltende arzneimittel
RU93057724A (ru) Фармацевтическая композиция, способ ее получения и способ лечения
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
CA2098302A1 (en) Medicaments
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
SE9901573D0 (sv) New compounds
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
GR3015014T3 (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
MY133438A (en) Morpholinobenzamide salts
RU96121556A (ru) Фармацевтические составы, содержащие ранитидин в низких дозах
MY145885A (en) Controlled release formulations for oral administration
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee